ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1561

Factors Influencing Implementation of Intensive Treatment Strategies for Early Rheumatoid Arthritis

Sabrina Meyfroidt1, Diederik De Cock1, Kristien Van der Elst2, Laura van Hulst3, Marlies Hulscher3, Johan Joly4, Rene Westhovens5 and Patrick Verschueren5, 1Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, 2Department of Development and Regeneration, Neuro-musculo-skeletal Research Unit, University Hospitals KULeuven, Leuven, Belgium, 3Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 4University Hospitals Leuven on behalf of the CareRA Study Group, Leuven, Belgium, 5Rheumatology, University Hospitals KULeuven, Leuven, Belgium

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Factors Associated with Rheumatoid Arthritis

Session Type: Abstract Submissions (ARHP)

Background/Purpose: Despite the availability and demonstrated effectiveness of intensive treatment strategies for early rheumatoid arthritis (RA), a discrepancy seems to exist between theoretical acceptance and practical implementation. Limited studies have looked at factors influencing the implementation of intensive treatment strategies for early RA in daily practice. The purpose of this study was to explore and identify these factors across different healthcare settings in Flanders. 

Methods: This study involved rheumatologists, nurses and patients participating in the CareRA trial, a multicentre RCT comparing different intensive treatment strategies for early RA based on the original Cobra step down schedule with conventional DMARDs (MTX+Sulphasalazine, MTX+Leflunomide, MTX monotherapy) plus step-down glucocorticoids. Two qualitative research methods were used, including semi-structured interviews and observations at outpatient clinics. Each interview was recorded, transcribed literally and analyzed thematically. 

Results: We interviewed 26 rheumatologists, 6 nurses and 24 RA patients and observed interactions between 5 rheumatologists and their patients at consultation. Greatest facilitators reported by rheumatologists and nurses included available scientific evidence, personal faith in treatment strategy, colleague support and low cost of medication. For patients, trust in caregiver was a facilitator, as well as faith in the treatment strategy. Rheumatologists had no doubts about the value of MTX but some questioned the combination strategy, others the effectiveness or/and the dosage of individual compounds. Patients were only in doubt of glucocorticoids and MTX. Additional barriers for rheumatologists included fear for patients’ preconceptions, concerns of applicability to the individual patient, break in routine, interference with organizational structures and processes, time constraints and lack of financial support.

Conclusion: The factors emerging from our study highlight the complexity of implementing intensive treatment strategies for early RA in daily clinical practice. Future improvement strategies should capitalize on the facilitators identified while at the same time addressing the barriers. The generalizability of these findings to other health care systems needs further examination.


Disclosure:

S. Meyfroidt,
None;

D. De Cock,
None;

K. Van der Elst,
None;

L. van Hulst,
None;

M. Hulscher,
None;

J. Joly,
None;

R. Westhovens,
None;

P. Verschueren,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/factors-influencing-implementation-of-intensive-treatment-strategies-for-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology